Eli Lilly and Company (LLY) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Eli Lilly and Company (NYSE: LLY):

• 8/30/2025 – Eli Lilly and Company was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 8/27/2025 – Eli Lilly and Company was upgraded by analysts at HSBC Holdings plc from a “reduce” rating to a “hold” rating. They now have a $700.00 price target on the stock, up previously from $675.00.
• 8/27/2025 – Eli Lilly and Company was upgraded by analysts at Hsbc Global Res from a “moderate sell” rating to a “hold” rating.
• 8/22/2025 – Eli Lilly and Company was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 8/17/2025 – Eli Lilly and Company was downgraded by analysts at Daiwa Capital Markets from an “outperform” rating to a “neutral” rating. They now have a $700.00 price target on the stock.
• 8/17/2025 – Eli Lilly and Company was downgraded by analysts at Daiwa America from a “strong-buy” rating to a “hold” rating.
• 8/14/2025 – Eli Lilly and Company was upgraded by analysts at DZ Bank AG from a “hold” rating to a “strong-buy” rating.
• 8/13/2025 – Eli Lilly and Company had its price target lowered by analysts at Cantor Fitzgerald from $975.00 to $825.00. They now have an “overweight” rating on the stock.
• 8/13/2025 – Eli Lilly and Company had its price target lowered by analysts at Guggenheim from $942.00 to $875.00. They now have a “buy” rating on the stock.
• 8/11/2025 – Eli Lilly and Company had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $1,010.00 to $900.00. They now have a “buy” rating on the stock.
• 8/8/2025 – Eli Lilly and Company had its price target lowered by analysts at UBS Group AG from $1,050.00 to $895.00. They now have a “buy” rating on the stock.
• 8/7/2025 – Eli Lilly and Company had its “market perform” rating reaffirmed by analysts at Leerink Partners. They now have a $715.00 price target on the stock.
• 8/7/2025 – Eli Lilly and Company was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
• 7/26/2025 – Eli Lilly and Company was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 7/11/2025 – Eli Lilly and Company had its price target raised by analysts at Guggenheim from $936.00 to $942.00. They now have a “buy” rating on the stock.
• 7/10/2025 – Eli Lilly and Company had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $1,135.00 price target on the stock, up previously from $1,133.00.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company’s payout ratio is presently 39.22%.

Insider Buying and Selling at Eli Lilly and Company

In other news, Director Gabrielle Sulzberger purchased 117 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the purchase, the director directly owned 2,703 shares of the company’s stock, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Daniel Skovronsky purchased 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.